Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00207
|
|||||
| Drug Name |
Amiloride
|
|||||
| Synonyms |
3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); Amiclaran; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida; Amilorida [INN-Spanish]; Amiloride (INN); Amiloride (Na-Ca chanel blocker); Amiloride HCL; Amiloride [INN:BAN]; Amiloride hydrochloride hydrate; Amiloridum; Amiloridum [INN-Latin]; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Biduret (TN); Guanamprazin; Guanamprazine; MK-870 (Hydrochloride dihydrate); Midamor; Midamor (Hydrochloride dihydrate); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Congestive heart failure [ICD11:BD10] | Approved | [1] | |||
| High blood pressure [ICD11:BA00] | Approved | [1] | ||||
| Therapeutic Class |
Diuretics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C6H8ClN7O
|
|||||
| Canonical SMILES |
C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
|
|||||
| InChI |
InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
|
|||||
| InChIKey |
XSDQTOBWRPYKKA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 2016-88-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 229.63 | Topological Polar Surface Area | 159 | ||
| Heavy Atom Count | 15 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11110775
,11113372
,11120240
,11120728
,11121216
,11121637
,11122117
,11335357
,11360596
,11362706
,11362808
,11365268
,11365370
,11367830
,11367932
,11370683
,11370684
,11371426
,11373431
,11373683
,11375992
,11376094
,11461568
,11466035
,11467155
,11483872
,11485670
,11487934
,11490109
,11491947
,11493848
,14798141
,26751628
,26751629
,29284103
,3182570
,46391861
,46508156
,46516430
,47217018
,47217019
,47291344
,47440507
,47440508
,5866713
,621650
,7885870
,8162159
,838821
,9039
|
|||||
| ChEBI ID |
ChEBI:2639
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| 2-Oct | Transporter Info | Organic cation transporter 2 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | 2-Oct | Transporter Info | Km =95 microM | Human embryonic kidney cells (HEK293)-OCT2 | [3] | |
| References | ||||||
| 1 | Amiloride was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. | |||||
| 3 | Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1521-31. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.